Conditions: Age Related Macular Degeneration
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 9
Healthy volunteers: yes

Brief summary:
This is a single-masked study to compare intravitreally administered 0.5 mg ranibizumab to 2.0 mg ranibizumab in subjects who manifest persistent or recurrent macular fluid less than 30 days following treatment with intravitreal anti-VEGF therapy. Patients will be masked to their treatment assignment.

The study duration is anticipated to be 12 months and will enroll 30 subjects . Patients will be randomized 2:1 to either 2.0 mg ranibizumab or 0.5mg ranibizumab.

Detailed description:

Arms:
arm 1: Lucentis 2.0 mg arm 2: None

Interventions: intervention 1: Ranibizumab intervention 2: Ranibizumab
Intervention descriptions: intervention 1: 2.0 mg intervention 2: 0.5 mg

Protocol document: